Molecular hepatocyte disorders connected with primary liver carcinoma Sylwia Serafińska, Monika Pazgan-Simon, Krzysztof Simon Medical Science Review - Hepatologia 2009; 9 65-68 aaICID: 902246
Article type: Review article
IC™ Value: 3.04
Abstract provided by Publisher
Hepatocellular carcinoma is the fifth most common cancer in the world and the fourth cause of death. The global incidence of HCC is increasing. In Poland the number of patients suffering from HCC has not been determined. Liver cancer develops in a liver changed by chronic viral inflammation caused by HCV, HBv, nonalcoholic fatty liver disease, or toxic, autoimmunological, or hereditary liver cirrhosis. If there is more than one cause of liver illness, especially HBV/HCV, HBV/HDV, or HIV co-infection or alcohol intake, liver cancer will develop earlier Patients usually present few nonspecific symptoms and the majority of them have advanced disease with poor prognosis and not many treatment possibilities. Hepatocellular carcinoma is a very heterogeneous disease with different etiologies, structures, biological behaviors, and molecular carcinogenic mechanisms, among them the growth factor-stimulated receptor Tyrosine Kinase pathways, the PI3 kinase/AKT/mTOR pathway, the Wnt/beta-catenin pathway, the angiogenic signaling pathway, and many others. The focus here is on pathways important for molecular targeted therapy.